Glaukos, based in Aliso Viejo, California, specializes in innovative therapies for glaucoma and retinal diseases, employing 907 staff since its IPO on June 25, 2015. Their products include micro-invasive devices and dropless treatments to reduce intraocular pressure.
Based on our analysis, Glaukos Corporation has received an overvalued rating of 1 out of 5 stars. This assessment is supported by several key financial ratios that indicate underperformance relative to the sector.
The Price-to-Book (PB) Ratio for Glaukos stands at 10.78, significantly higher than the sector average of 2.69. A high PB ratio may suggest that a company's stock is overpriced compared to its book value, indicating potential valuation concerns for investors.
In terms of profitability, Glaukos has a Net Profit Margin of -38.17, while the sector sees a more favorable average of -138.53. Although both figures reflect losses, a less negative margin indicates that the sector as a whole is performing better in terms of managing expenses relative to its revenues.
The Return on Equity (ROE) for Glaukos is -19.09, compared to a sector average of -75.49. While both figures are negative, a less unfavorable ROE suggests that the sector is more efficient in generating returns for shareholders, indicating Glaukos's struggles in this area.
Furthermore, Glaukos’s Return on Assets (ROA) is -15.02, whereas the sector average is -48.51. Again, while both ratios reflect inefficiencies, Glaukos's performance is still below the sector average, highlighting ongoing challenges in asset utilization.
In summary, the higher PB ratio and negative profitability metrics relative to the sector signal valuation concerns for Glaukos.
This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued
More Signals
Feature in Progress
This section is under development. Check back soon for updates!